A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients
IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging
and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays
a central role in maintaining the proper folding, function and viability of various "client
proteins". Many of the client proteins stabilized by Hsp90 are oncoproteins and
cell-signaling proteins important in cancer cell proliferation and cancer cell survival.
This clinical trial will study the effects of IPI-504 in a molecularly defined sub-group of
patients who carry client proteins found in non-small cell lung cancer.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine potential anti-tumor activity of IPI-504 in molecularly defined sub-groups of patients by RECIST criteria
Every 6 weeks
No
Lecia Sequist, MD
Principal Investigator
Massachusetts General Hospital
United States: Food and Drug Administration
IPI-504-03
NCT00431015
January 2007
December 2011
Name | Location |
---|---|
Yale Comprehensive Cancer Center | New Haven, Connecticut 06520-8028 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
Cedars-Sinai Medical Center | Los Angeles, California 90048 |
Hackensack University Medical Center | Hackensack, New Jersey 07601 |
Mount Sinai Comprehensive Cancer Center | Miami Beach, Florida 33140 |
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
Seattle Cancer Care Alliance | Seattle, Washington 98109 |
Medical College of Georgia | Augusta, Georgia 30912 |
H. Lee Moffitt Cancer Center | Tampa, Florida 33612 |
Mary Crowley Cancer Research Centers - Baylor | Dallas, Texas 75246 |
Mary Crowley Cancer Research Centers - Medical City | Dallas, Texas 75201 |